VGX International announces IND filing of VGX-1027

Published: 2007-12-24 06:57:00

Updated: 2007-12-24 06:57:00

VGX International announced on December 20 that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-1027 in healthy volunteers.

VGX-1027 is the company's lead drug candidate for the treatment of rheum...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK